COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for
COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered
especially against RNA viruses .It was known that convalescent plasma does not only
neutralize the pathogens but provide passive immunomodulatory properties that allows the
recipient to control the exaggerated inflammatory cascade. However, still there is a lack of
understanding of the mechanism of action of CCP therapeutic components. Reports from open
label trials and case series show that CCP is safe and might be effective in severe cases
with COVID-19 . Therefore, the World health organisation (WHO) and Food and Drug
Administration (FDA) issued guidelines for the CCP usage and standardised the donor selection
, which was further supported by Emergency use Authorisation (EUA) .
Therefore, the aim in the current study is to assess the effect of CCP on time to clinical
improvement, hospital mortality and to evaluate the changes on oxygen saturation and
laboratory markers (lymphocyte counts and C-reactive protein) compared with standard
treatment alone in patients with moderate or severe COVID-19 disease.